The present study will be focused to define the underlying mechanism of resistance in the malignant cells by analyzing the process of proliferation and differentiation in conjunction with the gene profiling and definition of new molecular markers.
ID
Source
Brief title
Condition
- Leukaemias
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Cellular proliferation and differentiation
- Gene profiling studies
- Molecular markers
Secondary outcome
not applicable
Background summary
Patients treated for leukemia and myelodysplasia have still an unfavorable
prognosis despite treatment with intensive chemotherapy and allogenic stem cell
transplantation. These results are in general not related to the incapability
to treat the patients with chemotherapy but due to the fact that the malignant
cells re-emerge 6 - 12 months after cessation of therapy. These findings
indicate that the malignant cells, at least a small subpopulation of them, are
intrinsic resistant to the applied therapeutic modalities. Further knowledge
regarding the underlying mechanisms of resistance might be highly relevant for
further improvements in treatment results for these patients. Especially
additional information of the cellular and molecular mechanism that operate in
these resistant cells.
Study objective
The present study will be focused to define the underlying mechanism of
resistance in the malignant cells by analyzing the process of proliferation and
differentiation in conjunction with the gene profiling and definition of new
molecular markers.
Study design
In patients diagnosed with AML or MDS additional bone marrow cells (20 ml) will
be collected during the standard diagnostic bone marrow test.
Study burden and risks
At the standard procedure of diagnostic bone marrow punction 20 ml extra marrow
is drawn. This increases the procedure with 2 minutes. There are no additional
punctions done.
Hanzeplein 1
Groningen 9713 GZ
NL
Hanzeplein 1
Groningen 9713 GZ
NL
Listed location countries
Age
Inclusion criteria
AML/MDS patients undergoing a diagnostic bone marrow-biopsy
Exclusion criteria
Age < 18 years
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL43844.042.13 |